JP2022534086A5 - - Google Patents
Info
- Publication number
- JP2022534086A5 JP2022534086A5 JP2021569934A JP2021569934A JP2022534086A5 JP 2022534086 A5 JP2022534086 A5 JP 2022534086A5 JP 2021569934 A JP2021569934 A JP 2021569934A JP 2021569934 A JP2021569934 A JP 2021569934A JP 2022534086 A5 JP2022534086 A5 JP 2022534086A5
- Authority
- JP
- Japan
- Prior art keywords
- cnot3
- expression
- composition according
- antisense oligomer
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025041378A JP2025085741A (ja) | 2019-05-27 | 2025-03-14 | 新規の網膜色素変性処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901804A AU2019901804A0 (en) | 2019-05-27 | Novel Retinitis Pigmentosa Treatment | |
| AU2019901804 | 2019-05-27 | ||
| AU2019903812 | 2019-10-10 | ||
| AU2019903812A AU2019903812A0 (en) | 2019-10-10 | Novel Retinitis Pigmentosa Treatment | |
| PCT/AU2020/050516 WO2020237294A1 (en) | 2019-05-27 | 2020-05-25 | Novel retinitis pigmentosa treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025041378A Division JP2025085741A (ja) | 2019-05-27 | 2025-03-14 | 新規の網膜色素変性処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534086A JP2022534086A (ja) | 2022-07-27 |
| JP2022534086A5 true JP2022534086A5 (enExample) | 2023-06-01 |
| JP7652713B2 JP7652713B2 (ja) | 2025-03-27 |
Family
ID=73553023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569934A Active JP7652713B2 (ja) | 2019-05-27 | 2020-05-25 | 新規の網膜色素変性処置 |
| JP2025041378A Pending JP2025085741A (ja) | 2019-05-27 | 2025-03-14 | 新規の網膜色素変性処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025041378A Pending JP2025085741A (ja) | 2019-05-27 | 2025-03-14 | 新規の網膜色素変性処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12559747B2 (enExample) |
| EP (1) | EP3976789A4 (enExample) |
| JP (2) | JP7652713B2 (enExample) |
| KR (1) | KR20220012276A (enExample) |
| CN (1) | CN113891940B (enExample) |
| AU (1) | AU2020285470B2 (enExample) |
| BR (1) | BR112021023936A2 (enExample) |
| CA (1) | CA3141633A1 (enExample) |
| IL (1) | IL288442A (enExample) |
| SG (1) | SG11202112946VA (enExample) |
| WO (1) | WO2020237294A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12559747B2 (en) * | 2019-05-27 | 2026-02-24 | Vision Pharma Pty Ltd | Retinitis pigmentosa treatment |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| WO2025043278A1 (en) * | 2023-08-25 | 2025-03-06 | PYC Therapeutics Limited | Gene-mediated conditions |
| WO2026090034A1 (en) * | 2024-10-21 | 2026-04-30 | Vision Pharma Pty Ltd | Agents for treatment of optic conditions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| RU2034835C1 (ru) | 1992-03-09 | 1995-05-10 | Научно-исследовательский и проектный институт мономеров с опытным заводом | СПОСОБ ПОЛУЧЕНИЯ β -КАРОТИНА |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2011349464B2 (en) | 2010-12-20 | 2016-07-07 | The General Hospital Corporation | Polycomb-associated non-coding RNAS |
| WO2013027104A1 (en) | 2011-08-25 | 2013-02-28 | Db Equipment As | Accessory bag having reinforced sidewalls and variable length |
| US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| US12559747B2 (en) * | 2019-05-27 | 2026-02-24 | Vision Pharma Pty Ltd | Retinitis pigmentosa treatment |
| KR20220104677A (ko) * | 2019-08-19 | 2022-07-26 | 스톡 테라퓨틱스, 인크. | 스플라이싱 및 단백질 발현을 조절하기 위한 조성물 및 방법 |
| JP2023529026A (ja) * | 2020-06-01 | 2023-07-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用 |
| CN113584038B (zh) * | 2021-09-09 | 2023-11-14 | 深圳雅济科技有限公司 | 一种治疗视网膜疾病的反义寡核苷酸组合及其应用 |
-
2020
- 2020-05-25 US US17/614,495 patent/US12559747B2/en active Active
- 2020-05-25 WO PCT/AU2020/050516 patent/WO2020237294A1/en not_active Ceased
- 2020-05-25 EP EP20813543.4A patent/EP3976789A4/en active Pending
- 2020-05-25 AU AU2020285470A patent/AU2020285470B2/en active Active
- 2020-05-25 BR BR112021023936A patent/BR112021023936A2/pt unknown
- 2020-05-25 SG SG11202112946VA patent/SG11202112946VA/en unknown
- 2020-05-25 CN CN202080040006.5A patent/CN113891940B/zh active Active
- 2020-05-25 CA CA3141633A patent/CA3141633A1/en active Pending
- 2020-05-25 JP JP2021569934A patent/JP7652713B2/ja active Active
- 2020-05-25 KR KR1020217040991A patent/KR20220012276A/ko active Pending
-
2021
- 2021-11-25 IL IL288442A patent/IL288442A/en unknown
-
2024
- 2024-07-31 US US18/790,933 patent/US12649922B2/en active Active
-
2025
- 2025-03-14 JP JP2025041378A patent/JP2025085741A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021290279B2 (en) | Reducing intron retention | |
| US20240033378A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| US6727355B2 (en) | Pharmaceutical composition for treatment of Duchenne muscular dystrophy | |
| JP2020189874A (ja) | 状態および疾患の処置のためのアンチセンスオリゴマー | |
| US6365345B1 (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role | |
| JP2022106803A (ja) | アラジール症候群の処置のためのアンチセンスオリゴマー | |
| JP7054675B2 (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JPH11513889A (ja) | タンパク質翻訳のアンチセンス阻害のための組成物および方法 | |
| TWI837102B (zh) | 用於反義遞送之細胞穿透肽 | |
| WO2007056829A1 (en) | Multitargeting interfering rnas having two active strands and methods for their design and use | |
| JP2019500346A (ja) | 腎臓病の処置のための組成物と方法 | |
| JPH09503391A (ja) | 多薬剤耐性関連タンパク質のオリゴヌクレオチド調整 | |
| TW202019442A (zh) | 用於反義遞送之三聚合肽 | |
| JP2022533358A5 (enExample) | ||
| CN115867657A (zh) | 用于治疗疾患和疾病的opa1反义寡聚物 | |
| JP2022522205A (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| WO2022248879A1 (en) | Composition and method for adar-mediated rna editing | |
| JP2021510512A5 (enExample) | ||
| CN119365598A (zh) | 用于治疗单基因神经发育障碍的组合物和方法 | |
| CN118043461A (zh) | 方法 | |
| WO2005004913A1 (ja) | デコイを含む薬学的組成物およびその使用方法 | |
| CN117980479A (zh) | 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体 | |
| EP0807172A1 (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
| US12163132B2 (en) | Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19 |